Panel of 134 fibrosis-associated genes

The Panel of 134 fibrosis-associated genes refers to a specific transcriptomic signature or a curated set of genetic markers used to study the molecular mechanisms of fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and liver cirrhosis. This panel typically includes genes involved in the inflammatory response, myofibroblast activation, and the remodeling of the extracellular matrix (ECM) (Wynn, 2008, J. Pathol.). For instance, a 134-gene signature has been identified in research to distinguish IPF from other lung conditions and to predict patient survival (Guenther et al., 2012, Chest). It is not a single therapeutic target but a diagnostic or research tool used to measure the expression levels of multiple genes simultaneously to assess disease severity or drug response (Gharaee-Kermani et al., 2009, Methods Mol. Med.). Common components of such panels include transforming growth factor-beta (TGF-beta) signaling molecules, matrix metalloproteinases (MMPs), and various collagen subtypes. Because it represents a broad array of biological functions and molecular classes, it is utilized for high-throughput screening and transcriptomic profiling rather than being directly modulated by a single pharmacological agent.

Other names

Fibrosis gene expression panel134-gene fibrosis signatureFibrosis-related gene setIPF 134-gene signature

Not applicable as this is a gene expression panel used for diagnostic or research profiling rather than a single druggable target.